A. Goodman

发表

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

C. Caldas, E. Provenzano, J. Abraham, 2017, The Lancet. Oncology.

Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial

D. Rea, C. Poole, I. Ahmed, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.

J. Dunn, J. Marsden, A. Burton, 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

J. Yarnold, C. Coles, N. Somaiah, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Kilovoltage imaging of implanted fiducials to monitor intrafraction motion with abdominal compression during stereotactic body radiotherapy for GI tumors

Mageras, Gikas, Karyn, 2017 .

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. Dziewulski, M. Gore, M. Highley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015)

J. Yarnold, J. Haviland, J. Bliss, 2018, International Journal of Radiation Oncology, Biology, Physics.

OC-0595: FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy:3-year normal tissue effects

E. Sawyer, J. Yarnold, C. Coles, 2018 .

The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ

M. Cooper, J. Dunn, O. Gilleard, 2008, World journal of surgical oncology.

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

E. Sawyer, J. Yarnold, C. Coles, 2020, The Lancet.

Prospective Randomized Comparison of Dacarbazine (DTIC) Versus DTIC Plus Interferon-Alpha (IFN-α) in Metastatic Melanoma

J. Dunn, J. Marsden, A. Burton, 2001 .

UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.

J. Larkin, P. Nathan, P. Lorigan, 2016 .

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

J. Yarnold, J. Haviland, J. Bliss, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

R. Plummer, S. Leyvraz, P. Lorigan, 2019, Annals of Oncology.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

C. Caldas, E. Provenzano, J. Abraham, 2019, The Lancet.

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).

Joanne S Haviland, John R Yarnold, J. Yarnold, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.

J. Larkin, P. Nathan, P. Lorigan, 2013 .

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial

A. Cross, Aaron E Miller, M. Goldman, 2023, The Lancet Neurology.

One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.

J. Haviland, I. Syndikus, A. Brunt, 2023, Health technology assessment.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

M. Gore, A. Dalgleish, P. Nathan, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.